Resources For AIDS Ther.& Dev. : Conf. In Vitro Evaluations HIV Ther.

艾滋病治疗资源。

• 批准号: 8550719
• 负责人: ROGER PTAK
• 金额: $ 41.54万
• 依托单位: SOUTHERN RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-30 至 2013-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8550719
• 关键词: Acquired Immunodeficiency Syndrome; Anti-HIV Therapy; Antiviral Agents; Cells; Classification; Contracts; Development; Drug Interactions; Drug resistance; Evaluation; FDA approved; Goals; HIV; HIV drug resistance; Human; In Vitro; Laboratories; Parents; Pharmaceutical Preparations; Resources; Virus; base; cell type; cytotoxicity; drug sensitivity; drug testing; in vitro Assay; in vitro activity; receptor

This contract performs in vitro confirmatory testing of drug substances submitted to DAIDS for further development as potential anti-HIV therapies. The goal is to independently confirm the initial observation of anti-HIV activity of promising drug substances and then examine the spectrum of in vitro activity in multiple cell types against panels of laboratory and/or primary HIV isolates representing viruses with different co-receptor usage, clade classification, and/or drug sensitivity. In addition, potential drug-drug interactions shall be examined and drug-resistant HIV isolates shall be made for the most promising drug substances.

该合同对提交给DAIDS的原料药进行体外确认测试，以进一步开发为潜在的抗HIV疗法。目的是独立确认有前景原料药抗HIV活性的初步观察结果，然后针对代表不同共受体使用、进化枝分类和/或药物敏感性的病毒的实验室和/或原代HIV分离株组，检查多种细胞类型中的体外活性谱。此外，应检查潜在的药物相互作用，并应制备耐药HIV分离株用于最有前途的原料药。